文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

复发性胶质母细胞瘤的二次手术：真实生活中患者选择标准的观察性研究。

Second surgery for relapsed glioblastoma: an observational study on criteria for patient selection in real life.

机构信息

Neurosurgery Unit, IRCCS Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144, Rome, Italy.

Neuro-Oncology Unit, IRCCS Regina Elena National Cancer Institute, via Elio Chianesi 53, 00144, Rome, Italy.

出版信息

Future Oncol. 2024;20(22):1565-1573. doi: 10.1080/14796694.2024.2358743. Epub 2024 Jun 11.

DOI:10.1080/14796694.2024.2358743
PMID:38861296
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11457679/
Abstract

There is little consensus on salvage management of glioblastoma after recurrence, for lack of evidence. A retrospective study of treatments in patients with recurrent glioblastoma. Surgery at recurrence was related to better overall survival (OS) and progression-free survival (PFS). Surgery at recurrence, Karnofsky index, methylation status, younger age at diagnosis and number of chemotherapy cycles were positive factors for OS and PFS. The benefit of OS was relevant for a second surgery performed at least 9 months after the first one. Systemic treatments after the second surgery were linked to an improved PFS. Younger age, Karnofsky index, methylation status and a median time between surgeries ≥9 months may be criteria for eligibility for surgery at recurrence.

摘要

由于缺乏证据，对于复发性胶质母细胞瘤的挽救性治疗管理，目前尚未达成共识。一项针对复发性胶质母细胞瘤患者治疗的回顾性研究。复发时的手术与更好的总生存期（OS）和无进展生存期（PFS）相关。复发时的手术、卡氏功能状态评分、甲基化状态、较年轻的诊断年龄和化疗周期数是 OS 和 PFS 的阳性因素。第二次手术至少在第一次手术后 9 个月进行时，OS 的获益才有意义。第二次手术后的系统治疗与改善的 PFS 相关。较年轻的年龄、卡氏功能状态评分、甲基化状态以及两次手术之间的中位时间≥9 个月，可能是复发性手术的适应证标准。

相似文献

[1]
Second surgery for relapsed glioblastoma: an observational study on criteria for patient selection in real life.

Future Oncol. 2024

[2]
Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?

Clin Neurol Neurosurg. 2018-4

[3]
O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications.

Neuro Oncol. 2010-2-1

[4]
Role of Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications.

Oncologist. 2017-4

[5]
MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.

J Neurooncol. 2017-7

[6]
Patient outcomes following second surgery for recurrent glioblastoma.

Future Oncol. 2016

[7]
Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.

Surg Oncol. 2020-12

[8]
Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Neurosurg Focus. 2014-12

[9]
Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.

J Neurosurg. 2012-6-1

[10]
Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers.

J Neurooncol. 2024-5

本文引用的文献

[1]
Should Redo Surgery be Offered to Patients with Relapsed Glioblastoma? - Outcome Analyses of a Single Institution Comparative Cohort Study.

World Neurosurg. 2023-8

[2]
Repeat resection for recurrent glioblastoma in the temozolomide era: a real-world multi-centre study.

Br J Neurosurg. 2024-12

[3]
Analyzing the role of reoperation in recurrent glioblastoma: a 15-year retrospective study in a single institution.

World J Surg Oncol. 2022-12-4

[4]
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.

Cochrane Database Syst Rev. 2021-5-4

[5]
Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastoma.

Acta Neurol Belg. 2022-4

[6]
Second surgery for progressive glioblastoma: a multi-centre questionnaire and cohort-based review of clinical decision-making and patient outcomes in current practice.

J Neurooncol. 2021-5

[7]
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.

Nat Rev Clin Oncol. 2021-3

[8]
Assessing the efficacy of repeat resections in recurrent glioblastoma: a systematic review.

Neurosurg Rev. 2021-6

[9]
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Neuro Oncol. 2020-8-17

[10]
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.

Neuro Oncol. 2019-11-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索